Impact of renal function on antidiabetic drug selection in Japan: A real-world analysis using the J-DREAMS database - PubMed
6 hours ago
- #renal function
- #type 2 diabetes
- #antidiabetic drugs
- The study analyzed renal function-specific prescribing patterns of antidiabetic drugs in Japanese patients with type 2 diabetes using real-world data from the J-DREAMS registry (2015-2023).
- Among 24,868 patients, 36.1% had reduced renal function (eGFR <60 mL/min/1.73 m2). DPP-4 inhibitors were the most common first-line agents, followed by metformin and insulin.
- SGLT2 inhibitors and GLP-1 receptor agonists saw increased use as second-line therapies, with SGLT2 inhibitors being most frequent in the normal renal function group (25.6%) and GLP-1 receptor agonists ranking third in the reduced renal function group (15.9%).
- After propensity score matching, sulfonylureas, metformin, and thiazolidinediones were prescribed less frequently in the reduced renal function group, while SGLT2 inhibitor prescriptions were similar between groups.
- The study concluded that prescribing patterns in Japan have shifted toward earlier use of SGLT2 inhibitors and GLP-1 receptor agonists, with medications appropriately tailored to renal function.